Notas del episodio
Today we discuss a major development: Novo Nordisk, the company behind WeGovy and Ozempic, is pushing the FDA to stop compounding pharmacies from manufacturing the compounded medications, citing the complexity of manufacture. Critics say it is just a ploy to secure profits.
Palabras clave
semaglutidecompounded medicationschallengesmanufacturingstop manufactureconsequencescomplexity